AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 615918400 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery in PEX group
Number of subjects: 31
Study 615918400 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery in non-PEX group
Number of subjects: 31
Study 615918400 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery in both groups
Number of subjects: 31
Study 34839386 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet) adherence
Number of subjects: 2278
Study 34839386 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure reduction
Number of subjects: 2278
Study 34839386 — intervention group
Group type: EXPERIMENTAL
Intervention: Low density-lipoprotein cholesterol reduction
Number of subjects: 2278
Study 34839386 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight reduction
Number of subjects: 2278
Study 34020205 — intervention group
Group type: EXPERIMENTAL
Intervention: Active iTBS (1200 pulses per session, twice daily over ten weekdays)
Number of subjects: 56
Study 34020205 — intervention group
Group type: COMPARATOR
Intervention: Sham condition (magnetically shielded side of the coil and simultaneous transcutaneous electrical nerve stimulation)
Number of subjects: 56
Study 34020205 — intervention group
Group type: EXPERIMENTAL
Intervention: Active iTBS
Number of subjects: 56
Study 34020205 — intervention group
Group type: COMPARATOR
Intervention: Sham condition
Number of subjects: 56
Study 34020205 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall depressive symptoms in patients with depression
Number of subjects: 56
Study 32757049 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumatinib mesylate after a high-fat diet
Number of subjects: 12
Study 32757049 — intervention group
Group type: COMPARATOR
Intervention: Flumatinib mesylate in fasting state
Number of subjects: 12
Study 35727095 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg daily for 4 weeks followed by 40 mg for 8 weeks
Number of subjects: 89
Study 35727095 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg for 4 weeks followed by 20 mg for 8 weeks
Number of subjects: 89
Study 32716320 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimavanserin 34 mg once daily
Number of subjects: 171
Study 32716320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 35763324 — intervention group
Group type: EXPERIMENTAL
Intervention: Run4Love intervention (3-month program including cognitive behavioral stress management and exercise promotion via WeChat)
Number of subjects: 300
Study 35763324 — intervention group
Group type: COMPARATOR
Intervention: Usual care and a brochure on nutrition (control group)
Number of subjects: 300
Study 34483780 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI image analysis based on variable model algorithm
Number of subjects: 100
Study 34483780 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable model improvement algorithm
Number of subjects: 100
Study 34483780 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI images based on variable model algorithm
Number of subjects: 100
Study 34314906 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg intravenous ondansetron
Number of subjects: 120
Study 34314906 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg intravenous granisetron
Number of subjects: 120
Study 34314906 — intervention group
Group type: COMPARATOR
Intervention: 10 ml normal saline (placebo)
Number of subjects: 120
Study 32585185 — intervention group
Group type: EXPERIMENTAL
Intervention: Counsellor-led problem-solving intervention with supporting printed materials
Number of subjects: 251
Study 32585185 — intervention group
Group type: COMPARATOR
Intervention: Printed booklets alone (control group)
Number of subjects: 251
Study 34669209 — intervention group
Group type: EXPERIMENTAL
Intervention: Inebilizumab
Number of subjects: 0
Study 34669209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32736460 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper partial J‐shaped sternotomy
Number of subjects: 112
Study 32736460 — intervention group
Group type: COMPARATOR
Intervention: Median sternotomy
Number of subjects: 112
Study 35658022 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 154
Study 35658022 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 154
Study 35658022 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled Dulaglutide groups
Number of subjects: 154
Study 35658022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 35658022 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Number of subjects: 154
Study 35246123 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologics (mepolizumab, benralizumab, dupilumab)
Number of subjects: 135
Study 35246123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 34528335 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT) referral volume from PSCs
Number of subjects: 1541
Study 32363529 — intervention group
Group type: EXPERIMENTAL
Intervention: Linked Color Imaging (LCI) + White Light Imaging (WLI)
Number of subjects: 0
Study 32363529 — intervention group
Group type: COMPARATOR
Intervention: White Light Imaging (WLI)
Number of subjects: 0
Study 33419469 — intervention group
Group type: EXPERIMENTAL
Intervention: New experimental therapy
Number of subjects: 1516
Study 33419469 — intervention group
Group type: COMPARATOR
Intervention: Original experimental arm
Number of subjects: 1516
Study 33419469 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 1516
Study 32969541 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive-behavioral therapy (ICBT)
Number of subjects: 301
Study 32969541 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face cognitive-behavioral therapy (CBT)
Number of subjects: 301
Study 34397805 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI + CFAE
Number of subjects: 50
Study 34397805 — intervention group
Group type: COMPARATOR
Intervention: PVI only
Number of subjects: 50
Study 32936680 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydration (24-h fluid restriction, USG>1.020) in men
Number of subjects: 22
Study 32936680 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydration (24-h fluid restriction, USG>1.020) in women (FDehy)
Number of subjects: 22
Study 32936680 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydration (24-h fluid restriction, USG>1.020) in women (LDehy)
Number of subjects: 22
Study 32936680 — intervention group
Group type: COMPARATOR
Intervention: Euhydrated condition (USG<1.020) in men
Number of subjects: 22
Study 32936680 — intervention group
Group type: COMPARATOR
Intervention: Euhydrated condition (USG<1.020) in women (FDehy)
Number of subjects: 22
Study 32936680 — intervention group
Group type: COMPARATOR
Intervention: Euhydrated condition (USG<1.020) in women (LDehy)
Number of subjects: 22
Study 35357107 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple
Number of subjects: 0
Study 35357107 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey
Number of subjects: 0
Study 35357107 — intervention group
Group type: COMPARATOR
Intervention: Pure fructose powder
Number of subjects: 0
Study 32743954 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride 4 mg daily
Number of subjects: 15
Study 32743954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 36397397 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral patellar denervation (PD)
Number of subjects: 202
Study 36397397 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar resurfacing (PR)
Number of subjects: 202
Study 36397397 — intervention group
Group type: COMPARATOR
Intervention: Simple TKA (Control group)
Number of subjects: 202
Study 36397397 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (PD, PR, and Control)
Number of subjects: 202
Study 32162274 — intervention group
Group type: EXPERIMENTAL
Intervention: Remogliflozin etabonate 100 mg BID
Number of subjects: 612
Study 32162274 — intervention group
Group type: EXPERIMENTAL
Intervention: Remogliflozin etabonate 250 mg BID
Number of subjects: 612
Study 32162274 — intervention group
Group type: COMPARATOR
Intervention: Dapagliflozin 10 mg QD
Number of subjects: 612
Study 32162274 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 612
Study 35136294 — intervention group
Group type: EXPERIMENTAL
Intervention: Thulium fiber laser (TFL)
Number of subjects: 125
Study 35136294 — intervention group
Group type: COMPARATOR
Intervention: Holmium laser
Number of subjects: 125
Study 35430192 — intervention group
Group type: EXPERIMENTAL
Intervention: Significant valvular dysfunction
Number of subjects: 189
Study 35430192 — intervention group
Group type: COMPARATOR
Intervention: No significant valvular dysfunction (comparator group)
Number of subjects: 189
Study 35430192 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic stenosis
Number of subjects: 189
Study 35430192 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral regurgitation
Number of subjects: 189
Study 35430192 — intervention group
Group type: EXPERIMENTAL
Intervention: Valvular disease
Number of subjects: 189
Study 34387101 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased mean heart rate (HR)
Number of subjects: 994
Study 34387101 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate average real variability (HR-ARV)
Number of subjects: 994
Study 34387101 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 994
Study 32856041 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Restoration Program (FRP)
Number of subjects: 32
Study 36170688 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose glucocorticoids (methylprednisolone 10 mg/kg)
Number of subjects: 25
Study 36170688 — intervention group
Group type: COMPARATOR
Intervention: Low-dose glucocorticoids (dexamethasone 8 mg)
Number of subjects: 25
Study 32807666 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT)
Number of subjects: 24
Study 32807666 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study 33736734 — intervention group
Group type: EXPERIMENTAL
Intervention: Working in COVID-19 wards
Number of subjects: 3421
Study 33736734 — intervention group
Group type: EXPERIMENTAL
Intervention: Working in non-COVID-19 geriatrics and rehabilitation wards
Number of subjects: 3421
Study 33736734 — intervention group
Group type: COMPARATOR
Intervention: Office workers
Number of subjects: 3421
Study 33736734 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing assistants
Number of subjects: 3421
Study 33736734 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of public transportation
Number of subjects: 3421
Study 33736734 — intervention group
Group type: EXPERIMENTAL
Intervention: Community exposure to SARS-CoV-2
Number of subjects: 3421
Study 33736734 — intervention group
Group type: EXPERIMENTAL
Intervention: Working in a ward with a nosocomial COVID outbreak
Number of subjects: 3421
Study 33736734 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of respirators
Number of subjects: 3421
Study 32068442 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose ingestion
Number of subjects: 10
Study 32068442 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat ingestion
Number of subjects: 10
Study 32068442 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein ingestion
Number of subjects: 10
Study 32068442 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (non-operated)
Number of subjects: 10
Study 32068442 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat® with fat ingestion
Number of subjects: 10
Study 35960850 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight management program 'ShipShape'
Number of subjects: 178
Study 34592180 — intervention group
Group type: EXPERIMENTAL
Intervention: ramucirumab
Number of subjects: 309
Study 34592180 — intervention group
Group type: EXPERIMENTAL
Intervention: merestinib
Number of subjects: 309
Study 34592180 — intervention group
Group type: COMPARATOR
Intervention: pooled placebo
Number of subjects: 309
Study 32149863 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioning with continuous reinforcement (CRF)
Number of subjects: 140
Study 32149863 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioning with partial reinforcement (PRF)
Number of subjects: 140
Study 32149863 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterconditioning
Number of subjects: 140
Study 32149863 — intervention group
Group type: EXPERIMENTAL
Intervention: Extinction
Number of subjects: 140
Study 32149863 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioning with PRF
Number of subjects: 140
Study 32149863 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioning with CRF
Number of subjects: 140
Study 32149863 — intervention group
Group type: EXPERIMENTAL
Intervention: CRF and PRF
Number of subjects: 140
Study 32149863 — intervention group
Group type: COMPARATOR
Intervention: Sham-conditioning control group
Number of subjects: 140
Study 34193224 — intervention group
Group type: EXPERIMENTAL
Intervention: EIT group (individualized PEEP based on ventilation distribution)
Number of subjects: 117
Study 34193224 — intervention group
Group type: COMPARATOR
Intervention: Control group (low PEEP/FiO2 table)
Number of subjects: 117
Study 34193224 — intervention group
Group type: EXPERIMENTAL
Intervention: EIT group
Number of subjects: 117
Study 34193224 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 117
Study 34953166 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief video on health harms of WTS
Number of subjects: 238
Study 34953166 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief video on overcoming myths about WTS
Number of subjects: 238
Study 34953166 — intervention group
Group type: COMPARATOR
Intervention: No video (Control)
Number of subjects: 238
Study 32809976 — intervention group
Group type: EXPERIMENTAL
Intervention: HRZE treatment
Number of subjects: 69
Study 32809976 — intervention group
Group type: COMPARATOR
Intervention: Ineffective therapy
Number of subjects: 69
Study 33221378 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth factors (specific types not mentioned)
Number of subjects: 0
Study 33221378 — intervention group
Group type: EXPERIMENTAL
Intervention: ERBB–RAS–MAPK signal transduction
Number of subjects: 0
Study 33221378 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical analyses of single-cell responses
Number of subjects: 0
Study 33221378 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of true and randomized datasets
Number of subjects: 0
Study 32197616 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-consultation testing
Number of subjects: 878
Study 32197616 — intervention group
Group type: COMPARATOR
Intervention: Standard practices (control)
Number of subjects: 878
Study 34922193 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% additional loading of individual body mass
Number of subjects: 14
Study 34922193 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher loading conditions
Number of subjects: 14
Study 34444949 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat beta-glucans with high molar mass, used for 30 days
Number of subjects: 48
Study 34444949 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat beta-glucans with low molar mass, used for 30 days
Number of subjects: 48
Study 34444949 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48
Study 32748293 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazosentan (20 mg/h i.v. for 3 h)
Number of subjects: 36
Study 32748293 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazosentan (60 mg/h i.v. for 3 h)
Number of subjects: 36
Study 32748293 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (single oral dose of 400 mg)
Number of subjects: 36
Study 32748293 — intervention group
Group type: COMPARATOR
Intervention: Placebo (i.v. for 6 h)
Number of subjects: 36
Study 34040198 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-GI dietary advice
Number of subjects: 571
Study 34040198 — intervention group
Group type: COMPARATOR
Intervention: Usual antenatal care
Number of subjects: 571
Study 33957025 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% hydrogen peroxide mouthwash and 0.5% hydrogen peroxide nasal spray for 7 days
Number of subjects: 40
Study 33957025 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 40
Study 35848045 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot‐assisted mirror therapy (RMT)
Number of subjects: 24
Study 35848045 — intervention group
Group type: COMPARATOR
Intervention: Standard mirror therapy (MT)
Number of subjects: 24
Study 33676601 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg once every 3 weeks for 35 cycles
Number of subjects: 622
Study 33676601 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (capecitabine, eribulin, gemcitabine, or vinorelbine)
Number of subjects: 622
Study 33676601 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 622
Study 33676601 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 622
Study 35718575 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 249
Study 35718575 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 249
Study 35718575 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosphenytoin
Number of subjects: 249
Study 32731829 — intervention group
Group type: EXPERIMENTAL
Intervention: Incisional negative-pressure wound therapy (iNPWT)
Number of subjects: 0
Study 32731829 — intervention group
Group type: COMPARATOR
Intervention: Standard dressing
Number of subjects: 0
Study 34618367 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Cyperus rotundus essential oil (CREO)
Number of subjects: 153
Study 34618367 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroquinone (HQ)
Number of subjects: 153
Study 34618367 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cold cream)
Number of subjects: 153
Study 34727422 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (n=39)
Number of subjects: 78
Study 34727422 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (n=39)
Number of subjects: 78
Study 34727422 — intervention group
Group type: EXPERIMENTAL
Intervention: Open ketamine (for midazolam nonremitters)
Number of subjects: 78
Study 35421836 — intervention group
Group type: EXPERIMENTAL
Intervention: VISIT tool (intervention)
Number of subjects: 246
Study 35421836 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 246
Study 34316231 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine administration of 500 IU hCG (0.5 ml) before IUI
Number of subjects: 200
Study 34316231 — intervention group
Group type: COMPARATOR
Intervention: Control group received 0.5 ml of normal saline before IUI
Number of subjects: 200
Study 34316231 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 200
Study 35244365 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based balance training combined with pulmonary rehabilitation (PR-BT)
Number of subjects: 48
Study 35244365 — intervention group
Group type: COMPARATOR
Intervention: Home-based pulmonary rehabilitation (PR)
Number of subjects: 48
Study 34414368 — intervention group
Group type: EXPERIMENTAL
Intervention: QazCovid-in® vaccine (5 μg each, two doses, administered intramuscularly, 21 days apart)
Number of subjects: 244
Study 34414368 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 244
Study 34414368 — intervention group
Group type: EXPERIMENTAL
Intervention: QazCovid-in® vaccine (one dose on day 1)
Number of subjects: 244
Study 34414368 — intervention group
Group type: EXPERIMENTAL
Intervention: QazCovid-in® vaccine (two doses on day 1 and 21)
Number of subjects: 244
Study 34414368 — intervention group
Group type: EXPERIMENTAL
Intervention: QazCovid-in® vaccine (two doses on day 1 and 21) for subjects aged ≥50 years
Number of subjects: 244
Study 34414368 — intervention group
Group type: EXPERIMENTAL
Intervention: QazCovid-in® vaccine (one dose on day 1) for subjects aged ≥50 years
Number of subjects: 244
Study 34414368 — intervention group
Group type: EXPERIMENTAL
Intervention: QazCovid-in® vaccine (after second dose)
Number of subjects: 244
Study 35035473 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency rTMS over contralesional M1 (1 Hz) followed by 30 minutes of motor task practice (10 sessions within 2 weeks)
Number of subjects: 24
Study 35035473 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS followed by the same motor task practice
Number of subjects: 24
Study 34765666 — intervention group
Group type: EXPERIMENTAL
Intervention: Nx4 (Neurexan®)
Number of subjects: 45
Study 33097947 — intervention group
Group type: COMPARATOR
Intervention: Fish oil (2000 mg/d DHA + 400 mg/d EPA)
Number of subjects: 100
Study 33097947 — intervention group
Group type: COMPARATOR
Intervention: Curcumin (160 mg/d)
Number of subjects: 100
Study 33097947 — intervention group
Group type: COMPARATOR
Intervention: Combination of fish oil and curcumin
Number of subjects: 100
Study 33097947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 33737025 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg twice daily for extended thromboprophylaxis (ETP) after radical cystectomy
Number of subjects: 72
Study 33006618 — intervention group
Group type: EXPERIMENTAL
Intervention: No CMF group (breastfeeding without cow's milk formula)
Number of subjects: 312
Study 33006618 — intervention group
Group type: COMPARATOR
Intervention: CMF group (breastfeeding supplemented with cow's milk formula)
Number of subjects: 312
Study 33006618 — intervention group
Group type: EXPERIMENTAL
Intervention: No CMF group (with vitamin D levels above median)
Number of subjects: 312
Study 33006618 — intervention group
Group type: COMPARATOR
Intervention: CMF group (with vitamin D levels above median)
Number of subjects: 312
Study 33006618 — intervention group
Group type: EXPERIMENTAL
Intervention: No CMF group (highest quartile of total IgE)
Number of subjects: 312
Study 33006618 — intervention group
Group type: COMPARATOR
Intervention: CMF group (highest quartile of total IgE)
Number of subjects: 312
Study 35441485 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive orthopedic care group (n=63) including preoperative psychological counseling and preventative risperidone
Number of subjects: 128